ShockWave Medical Stock Forecast, Price & News

ShockWave Medical's stock was trading at $34.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SWAV shares have increased by 184.1% and is now trading at $97.83.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ShockWave Medical or view MarketBeat's top 5 stock picks.

Wall Street analysts have given ShockWave Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ShockWave Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

ShockWave Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for ShockWave Medical.

ShockWave Medical, Inc. (NASDAQ:SWAV) released its earnings results on Monday, November, 9th. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.17. The company had revenue of $19.60 million for the quarter, compared to analysts' expectations of $14.69 million. ShockWave Medical had a negative net margin of 126.34% and a negative return on equity of 35.68%. The firm's revenue was up 73.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.46) earnings per share.
View ShockWave Medical's earnings history.

7 analysts have issued 12-month target prices for ShockWave Medical's shares. Their forecasts range from $23.00 to $95.00. On average, they expect ShockWave Medical's share price to reach $69.00 in the next year. This suggests that the stock has a possible downside of 29.5%.
View analysts' price targets for ShockWave Medical.

ShockWave Medical saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 2,830,000 shares, an increase of 17.9% from the October 15th total of 2,400,000 shares. Based on an average daily trading volume, of 464,600 shares, the days-to-cover ratio is presently 6.1 days.
View ShockWave Medical's Short Interest.

Some companies that are related to ShockWave Medical include NovoCure (NVCR), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Nevro (NVRO), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Merit Medical Systems (MMSI) and Glaukos (GKOS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), The Walt Disney (DIS), Square (SQ), The Trade Desk (TTD), salesforce.com (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

ShockWave Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.68%), JPMorgan Chase & Co. (5.48%), Wells Fargo & Company MN (4.30%), Point72 Asset Management L.P. (2.04%), State Street Corp (1.93%) and Jennison Associates LLC (1.71%). Company insiders that own ShockWave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for ShockWave Medical.

SWAV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Allianz Asset Management GmbH, WCM Investment Management LLC, AXA S.A., BNP Paribas Arbitrage SA, First Trust Advisors LP, Bank Julius Baer & Co. Ltd Zurich, and SG Americas Securities LLC. Company insiders that have sold ShockWave Medical company stock in the last year include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Isaac Zacharias, and Sofinnova Capital Vii Fcpr.
View insider buying and selling activity for ShockWave Medical.

SWAV stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Federated Hermes Inc., Lord Abbett & CO. LLC, State Street Corp, Great West Life Assurance Co. Can, Charles Schwab Investment Management Inc., and Voloridge Investment Management LLC.
View insider buying and selling activity for ShockWave Medical.

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SWAV stock can currently be purchased for approximately $97.83.

ShockWave Medical has a market capitalization of $3.35 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. ShockWave Medical employs 284 workers across the globe.

The official website for ShockWave Medical is www.shockwavemedical.com.

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]